STAT3 and hepatocellular carcinoma: Considering that the increase of liver inflammation was accompanied with p‐STAT3 up‐regulation of tumour tissues for HCC patients (Figure 7F), STAT3 inhibitor may improve the sorafenib efficacy for HCC patients with marked liver inflammation.